Enterprise contract manufacturing pipelines for pharmaceutical, nutricosmetic, and clinical grade botanical active compounds.
Overcoming botanical batch variability through precision physics, automated chromatographic isolation, and verifiable molecular integrity.
Global supply chains for phytopharmaceuticals often falter due to wild-harvest variability, inconsistent seasonal bioactivity, and non-linear extraction losses during industrial scale-up. Unstandardized thermal degradation and indiscriminate mass transfer in conventional maceration lead to unacceptable batch failures. MedGence solves this via rigorous thermal profiling, closed-loop extraction loops, and predictive thermodynamic yield modeling.
Our OEM manufacturing frameworks incorporate multi-stage macroporous resin adsorption, countercurrent liquid-liquid extraction, continuous ceramic micro-membrane filtration, and supercritical CO₂ fluid systems. By fine-tuning pressure gradients, solvent polarity regimes, and flow mechanics, we consistently harvest pure alkaloids, high-density polysaccharides, polyphenols, and delicate terpene fractions while preserving biological potency.
Empirical substantiation is woven directly into every OEM run. Using automated HPTLC quantitative fingerprinting, high-resolution HPLC-MS, and GC-FID, our analytical centers correlate phytochemical profiles against certified pharmacopeia reference standards (USP, Ph. Eur., ChP). This ensures that heavy metal residues, pesticides, solvent limits, and chiral purity meet zero-defect regulatory standards worldwide.
Navigating the paradigm shift toward natural pharmacotherapy, cross-border supply vulnerability, and the imperative for green engineering.
The global botanical therapeutics and nutraceutical ingredients industry is projected to surpass USD 150 billion by 2030. Escalating consumer resistance to synthetics, alongside regulatory expansion of botanical drug registration under FDA 21 CFR Part 314 Subpart I, has triggered widespread demand for reliable OEM manufacturers capable of delivering synthetic-level uniformity from complex, wild-derived botanical inputs.
Post-pandemic pharmaceutical supply chains face escalating geopolitical tariffs and export volatility. As an integrated OEM & CRO partner based in Changsha, Hunan—the nexus of raw material origin corridors—MedGence establishes decentralized regional sourcing networks, direct farm-to-extraction custody models, and multi-facility contingency buffers to insulate global clients from geopolitical disruptions.
Industrial botanical extraction requires vast resource stewardship. Our manufacturing plants integrate continuous organic solvent recovery loops operating at >95% recovery rates, closed-loop thermal heat exchange arrays, and low-waste byproduct circularity (transforming spent biomass into agricultural compost or secondary biomaterials), meeting strict international ESG standards and corporate decarbonization mandates.
Decades of laboratory discoveries scaled reliably into multi-ton commercial deliverables.
Bridging Chinese botanical processing prowess with stringent regional health agency requirements.
Full conformance with 21 CFR Part 111 (Dietary Supplements) and Part 211 (Finished Pharmaceuticals). Complete toxicological dossiers (LD50, 90-day repeat dose, Ames assays) compiled for seamless New Dietary Ingredient (NDI) and GRAS (Generally Recognized as Safe) notifications.
Active substance dossiers aligned with EMA/HMPC Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC). Rigorous multi-residue pesticide limits via GC-MS/MS compliant with Ph. Eur. 2.8.13, ensuring smooth entry into mature EU pharmacies.
Comprehensive verification against China's NMPA standards for Classic Famous Prescriptions and Hospital Preparations, Australia’s TGA Listed Medicine guidelines, and Japan’s PMDA Kampo criteria, expediting cross-border registration across regional trade corridors.
Robust legal isolation under bi-lateral Non-Disclosure Agreements (NDAs). Proprietary formulation ratios, custom chromatography parameters, and purification steps are quarantined within air-gapped internal servers, ensuring client trade secrets remain permanently protected.
Customizing extraction purities, viscosity parameters, and dissolution profiles to exact commercial delivery forms.
We configure active herbal fractions for immediate bio-absorption in dietary supplements. Utilizing cyclodextrin micro-encapsulation and liposomal emulsification, our manufacturing process eliminates unpalatable bitterness and protects oxidation-sensitive polyphenols, making them ideal for high-shear encapsulation, clear RTD drinks, and soluble sachets.
For biopharmaceutical developers exploring new botanical chemical entities, we engineer multi-target active isolates supported by GLP toxicology, receptor-binding cellular screens, and Phase I–IV clinical study validation. This provides the robust evidence base required by regulatory agencies for formal botanical drug marketing approvals.
Supplying water-soluble, decolorized botanical fractions engineered for dermatological stability. Free from heavy metals, synthetic surfactants, and cytotoxic solvent traces, our botanical extracts pass 3D-reconstructed human skin irritation models, meeting the strict requirements of premier prestige clean-beauty brands.
Pioneering the convergence of artificial intelligence, synthetic biology, and PAT continuous extraction.
Employing machine learning algorithms to screen multi-component TCM chemical libraries against human enzyme targets, shortening discovery timelines from years to weeks.
Embedding In-line Process Analytical Technology (Near-Infrared and automated Raman sensors) to modulate temperature and flow in real time during extraction runs.
Integrating synthetic bio-catalysis and cellulase pre-treatment arrays to breach resilient botanical cell walls, elevating target ingredient yields by 35% without heat.
Transitioning primary pilot plants to 100% electrified, zero-emission heat pumps accompanied by complete closed-loop circular water purification loops.
Key technical, legal, and operational considerations for global buyers vetting MedGence CDMO facilities.
Explore our active service lines to contract customized extraction batches or initiate end-to-end pharmaceutical development.
